Biogen Inc

Entity type image
Type: Company
Name: Biogen Inc
First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Deloitte Recap Calls 2012 the 'Year of the Phase II'

SAN FRANCISCO Phase II deal values surpassed Phase III in 2012, leading a senior biopharma analyst for Deloitte Recap LLC, to say "2012 was certainly the year of the Phase II" in her talk summarizing Deloitte's analysis of 1,692 deals closed in 2012 at ... [Published Pharmacy Choice - Apr 30 2013]
First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Royalty Pharma Raises Offer for Elan to as Much as $12 Per ADR

Royalty Pharma, an investor in royalty streams from pharmaceuticals, raised its offer to buy Elan Corp. (ELN) to as much as $12 per American depositary receipt, threatening the Irish drugmaker’s plan to embark on its own acquisitions.The formal offer ... [Published Bloomberg - Apr 15 2013]

Quotes

The analyst, Jennifer Doyle, commented on the downward trend in Phase I deals, noting, "Phase I is a great time to buy if you're a pharma company. I think there's a lot of motivation for sellers to go as far as they can."

More Content

All (2) | News (2) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Deloitte Recap Calls 2012 the 'Year of the Phas... [Published Pharmacy Choice - Apr 30 2013]
Royalty Pharma Raises Offer for Elan to as Much... [Published Bloomberg - Apr 15 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.